Table 1 Characteristics of the patients
Median (range) or No. (%) | Median (range) or No. (%) | ||
|---|---|---|---|
Age, year | 57 (31–70) | Bortezomib | |
Gender | Exposed | 50 (100) | |
Male | 22 (44) | Refractory | 50 (100) |
Female | 28 (56) | Ixazomib | |
ECOG performance status | Exposed | 18 (36) | |
0 | 22 (44) | Refractory | 16 (32) |
1 | 23 (46) | Previous immunomodulatory drugs | |
2 | 5 (10) | Lenalidomide | |
Monoclonal type | Pomalidomide | ||
IgG | 25 (50) | Exposed | 7 (14) |
IgA | 14 (28) | Refractory | 6 (12) |
IgD | 2 (4) | Thalidomide | |
λ light chain | 6 (12) | Exposed | 23 (46) |
κ light chain | 3 (6) | Refractory | 20 (40) |
International Staging System | Previous anti-38 monoclonal antibodies | ||
I | 4 (8) | Daratumumab | |
II | 18 (36) | Exposed | 9 (18) |
III | 28 (56) | Refractory | 9 (18) |
Median time since diagnosis, months | 29.5 (4–162) | Previous ASCT | 20 (40) |
Extramedullary plasmacytomas | 7 (14) | Previous CAR T cell infusion | 5 (10) |
High-risk cytogenetic | 34 (68) | Penta-drug exposed | 4 (8) |
Bone marrow plasma cellså 50% | 11 (22) | Double-refractory disease | 50 (100) |
Detectable CD19 expression | 5 (10) | Triple-refractory disease | 9 (18) |
Tumor BCMA expression ≥ 50% | 30(60) | Penta-refractory disease | 4 (8) |
Previous therapies | 4 (2–11) | Refractory to the last line of therapy | 40 (80) |
Previous proteasome inhibitors | Relapse after the last treatment | 10 (20) |
